A Study of PF-06873600 in People With Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
Interventions: DRUG: PF-06873600|DRUG: Endocrine Therapy 1|DRUG: Endocrine Therapy 2
Sponsor: Pfizer